Jonathan Robertson

发表

Clinical Efficacy and Tolerability of a Novel Selective Corticosteroid in Atopic Dermatitis - Two Randomised Controlled Trials

M. Worm, K. Hardes, S. Dölle, 2015, Skin Pharmacology and Physiology.

Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach

E. Merlo-Pich, S. Zamuner, E. Ratti, 2014, Journal of psychopharmacology.

Bayesian approach multicentreMajor Depressive Disorder : Results from two randomised , placebo-controlled , double-blind , Evaluation of antidepressant properties of the p 38 MAP kinase inhibitor losmapimod

E. Merlo-Pich, S. Zamuner, E. Ratti, 2014 .

Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.

Joseph Cheriyan, David E Newby, Ruth Tal-Singer, 2016, British journal of clinical pharmacology.

Safety and pharmacology of a soluble epoxide hydrolase inhibitor

R. Tal-Singer, D. Newby, R. Mayer, 2015 .

EFFICACY OF VESTIPITANT IN PRIMARY INSOMNIA

H. Danker-Hopfe, L. Squassante, E. Merlo-Pich, 2013 .

Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers

J. Upward, A. Berges, Jonathan Robertson, 2012, Clinical pharmacology in drug development.

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury

P. Anand, B. Chizh, J. Palmer, 2011, European journal of pain.

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

R. Solari, S. Hodgson, A. Cahn, 2013, BMC Pharmacology and Toxicology.

The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction.

E. Bullmore, C. Dodds, C. Davies, 2013, The international journal of neuropsychopharmacology.

Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.

H. Danker-Hopfe, L. Squassante, E. Merlo-Pich, 2013, Sleep.